Palmitoylethanolamide (PEA)
Also known as: PEA, N-palmitoylethanolamine
A 2023 meta-analysis of double-blind randomized controlled trials (n=11 trials, combined N=774) reported that PEA reduced pain scores versus comparators. Small trials and systematic reviews report improvements in cognitive symptoms (PEA combined with luteolin) in long-COVID and mixed evidence for post‑COVID olfactory dysfunction. Overall the human clinical literature suggests analgesic effects and possible benefits in certain neurocognitive or neuroinflammatory contexts, but optimal dosing and long‑term effects remain uncertain.
Last reviewed: 2026-10-14 · 4 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Palmitoylethanolamide (PEA) is a naturally occurring fatty acid amide found in various tissues and available as an oral supplement. Randomized trial data synthesised in meta-analyses indicate benefits for chronic pain, and small clinical studies have investigated PEA combined with luteolin for cognitive symptoms and olfactory dysfunction after COVID-19.
Mechanism & Function
Mechanism of Action
Reported mechanisms in the literature propose anti‑inflammatory and neuro‑modulatory effects mediated by fatty‑acid‑amide signalling pathways and indirect modulation of endocannabinoid and mast‑cell activity; the clinical abstracts summarise effects consistent with analgesia and neuroprotection but do not provide primary mechanistic data.
Physiological Role
May modulate inflammatory signalling and neuroimmune activation associated with chronic pain and post‑infectious neurocognitive symptoms.
Primary Pathways
Performance / Health Relevance
Clinical evidence does not address athletic performance; relevance is primarily for symptom management (pain, cognitive symptoms, agitation) rather than performance enhancement.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- Not established (meta-analysis notes optimal dosing unknown)
- Optimal Range
- Not established
- Upper / Caution Level
- Not established
- Timing
- Not established
- Best Format
- Oral formulations (often plain PEA or PEA combined with luteolin in trials)
- Bioavailability
- Specific bioavailability data are not provided in the cited abstracts.
- Absorption Considerations
- Not described in the cited abstracts
Safety & Interactions
Side Effects
- •No major side effects attributed in the included meta-analysis; individual studies small so rare events cannot be excluded
Contraindications
- Not described in abstracts
Drug Interactions
- •Not described in abstracts; caution advised with concomitant pharmacotherapies
Who Should Avoid
- •Pregnant or breastfeeding people (no data in provided abstracts)
- •People on multiple prescription medications without medical advice
Monitoring
Monitor symptom response and any adverse effects; consult a clinician for use with other medications.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Palmitoylethanolamide (PEA) typically used or indicated?
Palmitoylethanolamide (PEA) is most commonly used for: Chronic pain (neuropathic and inflammatory), Adjunct for cognitive symptoms (eg, long-COVID brain fog), Adjunctive treatment for agitation in neurodevelopmental disorders. May modulate inflammatory signalling and neuroimmune activation associated with chronic pain and post‑infectious neurocognitive symptoms.
How does Palmitoylethanolamide (PEA) work?
Reported mechanisms in the literature propose anti‑inflammatory and neuro‑modulatory effects mediated by fatty‑acid‑amide signalling pathways and indirect modulation of endocannabinoid and mast‑cell activity; the clinical abstracts summarise effects consistent with analgesia and neuroprotection but do not provide primary mechanistic data.
What is the recommended dose of Palmitoylethanolamide (PEA)?
The optimal range is Not established. with a minimum effective dose of Not established (meta-analysis notes optimal dosing unknown). Best taken: Not established. Upper / caution level: Not established.
What are the side effects of Palmitoylethanolamide (PEA)?
Reported side effects include: No major side effects attributed in the included meta-analysis; individual studies small so rare events cannot be excluded. Monitoring: Monitor symptom response and any adverse effects; consult a clinician for use with other medications.
Does Palmitoylethanolamide (PEA) interact with medications?
Known or theoretical interactions: Not described in abstracts; caution advised with concomitant pharmacotherapies. Always check with a clinician before combining with prescription medication.
Who should avoid Palmitoylethanolamide (PEA)?
Palmitoylethanolamide (PEA) is generally not recommended for: Pregnant or breastfeeding people (no data in provided abstracts); People on multiple prescription medications without medical advice; and Not described in abstracts.
How strong is the evidence for Palmitoylethanolamide (PEA)?
Evidence level: Moderate (overall score 65/100), based on 4 indexed studies on SuppIndex.
Research & References (4)
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.
Systematic review and meta-analysis of double‑blind RCTs of PEA for chronic pain; 11 trials, combined N=774; primary outcome pain intensity.
Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.
Systematic review of interventions for long‑COVID brain fog; among various interventions, two studies reported that PEA combined with luteolin improved cognitive impairment.
Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
Living systematic review of interventions for persistent post‑COVID olfactory dysfunction; included two RCTs (total n=30) among which one intervention arm used palmitoylethanolamide plus luteolin.
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities.
Network meta‑analysis of pharmacotherapies for agitation in ASD or intellectual disability; risperidone plus palmitoylethanolamide was among treatments shown to reduce agitation versus placebo.
Related Ingredients
Other top-rated ingredients in General Health Ingredients.
Piperine
82/100A piperidine alkaloid (C₁₇H₁₉NO₃) that inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2E1), P-glycoprotein efflux transporters, and UDP-glucuronosyltransferases while enhancing intestinal permeability, digestive enzyme secretion, and splanchnic blood flow — collectively producing dramatic improvements in nutrient bioavailability.
CoQ10
78/100Endogenous lipid-soluble ubiquinone/ubiquinol that shuttles electrons in the mitochondrial respiratory chain and acts as a membrane antioxidant.
Beta-Glucan (Oat)
77/100Multiple randomized trials and meta-analyses report that ≥3 g/day oat beta-glucan lowers LDL and total cholesterol modestly. Acute feeding trials pooled in meta-analysis show dose- and molecular-weight–dependent reductions in postprandial glucose and insulin responses.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/palmitoylethanolamide-pea
SuppIndex. (2026). Palmitoylethanolamide (PEA): Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/palmitoylethanolamide-pea
Based on 4 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
PEA is often studied combined with luteolin; evidence for combinations beyond this is limited in the provided abstracts.